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The study investigated the therapeutic effect of hyperbaric oxygen (HBO) on anterior
ischemic optic neuropathy in a rodent model (rAION). rAION was laser-induced in one eye
of 63 mice.The fellow (uninjured) eye served as an internal control.Thirty-three mice under-
went two 90-min sessions of 100% oxygen (2 atm) treatment immediately following injury
and one session daily thereafter for up to 14 days. The remaining mice were untreated.
Retinas were harvested at different time points, and mRNA levels of various genes were
analyzed by real-time polymerase chain reaction and histologic study. Untreated mice: day
1 post-rAION – SOD-1 (oxidative-stress-related) decreased to 82% of control (uninjured
eye) levels (P < 0.05), Caspase-3 (proapoptotic) decreased to 89%, Bcl-xL mildly increased
(117%; all NS); day 3 – HO-1 and endothelial nitric oxide synthase (eNOS; ischaemia-related)
decreased to 74%, and Bcl-2-associated X protein, Caspase-3, and B-cell lymphoma 2
(Bcl-2; apoptotic) increased by 170, 120, and 111%, respectively (all NS); day 21 – HO-1
increased to 222% (NS) and eNOSdecreased to 48% (P < 0.05).Treatedmice: day 1 – SOD-
1 and Caspase-3 remained unchanged, Bcl-2 and Bcl-xL mildly increased (112 and 126%
respectively); day 3 –HO-1 and eNOS increased, apoptosis-related gene decreased; day 21
– SOD-1 decreased whereas eNOS increased (P < 0.05), and HO-1 increased to a lesser
degree thanwithout treatment. None of the oxygen-treated animals had retinal ganglion cell
loss or a decrease inThy-1 expression. In conclusion, HBO treatment after rAION induction
inﬂuences the expression of apoptosis-related genes as well as oxidative-stress-induced
and ischaemia-related genes and may exert a neuroprotective effect.
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INTRODUCTION
Anterior ischemic optic neuropathy (AION) andpressure-induced
glaucoma primarily affect the retinal ganglion cells (RGCs;
Kaushik et al., 2003; Levin, 2003). Several mechanisms are known
to mediate programmed death (apoptosis) of the RGCs, namely,
deprivation of neurotrophic factors, alterations in gene expres-
sion, and production of reactive oxygen species. However, RGC
death does not occur immediately after axonal injury, and a sig-
niﬁcant number of cells survive even several days, suggesting the
involvement of pro-survival factors as well. This assumption is
supported by studies showing that axotomy leads to molecular
events that are potentially destructive to RGCs but, at the same
time, induce changes that are potentially protective against cel-
lular injury (Levin, 1999). Identifying the processes that underlie
the regulation of cell survival may lead to innovative therapeutic
methods of neuroprotection (Levin, 1999).
Themechanisms of RGCdeath have been examined in different
models of optic nerve transection and crush (Bonfanti et al., 1996;
Chaudhary et al., 1999; Kermer et al., 1999), acute retinal ischemia
and reperfusion (Buchi, 1992; Adachi et al., 1996; Selles-Navarro
et al., 1996), and chronic elevation of intraocular pressure (IOP;
Morrison et al., 1997; Mittag et al., 2000). Recently, we charac-
terized a rodent model of AION (rAION) wherein axonal stroke
was induced by selective illumination of the optic disk in the pres-
ence of a photoactive substance (Bernstein et al., 2003; Kaushik
et al., 2003). The retinal blood supply remained intact. Because
the ﬁnal common pathway of axonal damage is RGC death, this
model made it possible to investigate the molecular changes that
occur in the retina following damage to the optic nerve, with and
without treatment.
The kinetics of the signaling pathways involved in apoptosis
after retinal ischemia have recently been investigated (Produit-
Zengafﬁnen et al., 2009). Extensive molecular studies revealed
that members of the B-cell lymphoma 2 (Bcl-2) gene family
play a critical role in the activation and control of ganglion cell
death (Nickells et al., 2008) and that Bcl-2-related family mem-
bers are differently regulated in the early and late phases after an
ischemic retinal insult (Produit-Zengafﬁnen et al., 2009). Similar
to primary RGC degeneration, secondary degeneration following
optic nerve damage was characterized by activation of Caspase-3,
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downregulation of the pro-survival genes Bcl-2 and Bcl-xL, and
upregulation of the proapoptotic genes Bcl-2-associated X protein
(Bax) and Bad (Levkovitch-Verbin et al., 2010).
Oxygen is a critical substrate in the alleviation of hypoxia,
anoxia, and ischemia. However, it also exerts deleterious effects
during reperfusion of previously ischemic tissues. Adding to this
paradox is a spate of pioneering works identifying hyperoxygena-
tion (hyperoxia) and its metabolites as solely and purposefully
yielding cellular and clinical beneﬁts, particularly in ischemic
reperfusion injuries (Yogaratnam et al., 2006). These effects were
further improved by a novel technology, called hyperbaric oxygen
(HBO), which involves the administration of oxygen at supra-
atmospheric pressures in high concentrations (Yogaratnam et al.,
2006). Although the concept of HBO was introduced in the mid-
twentieth century, it is only in the past decade or so that its
therapeutic potential has been put to advantage for purposes of
cellular tolerance and neuroprotection.
Hyperbaric oxygen has been found to be a useful adjunct in
several models of renal, skeletal, and myocardial infarction (Yoga-
ratnam et al., 2006), and brain ischemic reperfusion injury (Hou
et al., 2007; Singhal, 2007; Solmazgul et al., 2007; Vidigal et al.,
2007; Eschenfelder et al., 2008), by improving oxygen perfusion
to the ischemic tissues. It currently serves as a primary or adju-
vant mode of treatment for various acute or chronic disorders.
Eye diseases are still among the off-label applications of HBO
despite cumulative evidence of its safety and efﬁcacy in patients
with retinal artery occlusion, cystoid macular edema secondary to
retinal vein occlusion, scleral thinning and necrosis after ptery-
gium surgery, orbital rhino-cerebral mucomycosis, non-healing
corneal edema, and anterior segment ischemia (Oguz and Sobaci,
2008). Its possible beneﬁt in some blinding diseases was noted as
well. In a review of its uses in the eye, Butler et al. (2008) sug-
gested various ocular disorders that may potentially beneﬁt from
HBO treatment, such as central retinal artery occlusion, radiation
optic neuropathy, and selected cases of ischemic optic neuropa-
thy. However, except in a few cases (Boschetti et al., 2006; Levy
and Miller, 2006), ﬁndings for radiation-induced neuropathy have
been disappointing (Danesh-Meyer, 2008). Beiran et al. (1995)
successfully treated two patients with AION using HBO. The same
group (Beiran et al., 2001) and others (Arnold and Levin, 2002)
reported that when applied early, HBO improved visual outcome
in patients with retinal arterial occlusion.
No methodologic investigations of HBO have been conducted
to date in ischemic retinas, although earlier ﬁndings from our
center highlighted the involvement of apoptosis in the cell loss
consequent to central retinal artery occlusion (Goldenberg-Cohen
et al., 2008). Prompted by the encouraging results in the literature,
we sought to investigate the neuroprotective effect of HBO in a
rAION.
MATERIALS AND METHODS
EXPERIMENTAL ANIMALS
Male wild-type C57/Bl6 mice aged 10–12 weeks were obtained for
the study from Harlan Laboratories (Jerusalem). All mice were
maintained and handled in accordance with the ARVO Statement
for the Use of Animals in Ophthalmic andVision Research and the
NIH guidelines. All animal protocols were approved by theAnimal
Research Committee of Rabin Medical Center.
RAION INDUCTION
Rodent model of AION was induced as previously described
(Goldenberg-Cohen et al., 2005). In brief, 63 mice were anes-
thetized with ketamine 80 mg/kg and xylazine 4 mg/kg. A plastic
custom-designed fundus corneal contact lens was used for direct
in vivo visualization of the retina and optic nerve head. After
intravenous administration of 0.03 mL of 2.5 mM rose bengal in
phosphate-buffered saline, the optic nerve head was illuminated
with argon green laser (532 nm) at the following speciﬁcations:
200μm spot size, 50 mW power, constant duration (0.1 s). rAION
was induced in the right eye of each animal; the fellow (uninjured)
eye served as an internal control.
HBO TREATMENT
Immediately after rAION induction, 33 mice were placed in a
HBO chamber specially designed for this experiment (Figure 1)
and exposed to two sessions of 100% oxygen (2 atm) for 90 min.
Thereafter treatmentwas repeated once daily for up to 14 days. The
remaining 30 mice were untreated and served as the comparison
group.
HISTOLOGICAL EXAMINATION
Sixteen mice were used for histological analysis. After euthaniza-
tion at 1, 3, 7, or 21 days, both eyes were enucleated and embedded
in parafﬁn or ﬁxed in 4% formaldehyde, placed overnight in
30% sucrose dissolved in phosphate-buffered saline at 4˚C, and
embedded in OCT compound (Tissue-Tek, sakura ﬁnerek). Three
sections (6μm each) from each eye were mounted on slides and
stained with hematoxylin and eosin for light microscopy analysis.
APOPTOSIS ASSAY
Longitudinal cross-sections from the parafﬁn-embedded eyes
were cut 6μm thick for in situ TdT-mediated dUTP nick
end-labeling assay (TUNEL; Roche Diagnostics, Mannheim,
FIGURE 1 | Hyperbaric oxygen chamber designed for mice.The mice
can be seen through the windows during treatment.
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Table 1 | Primer sequences used for RT-PCR analysis.
Gene Forward Reverse
Oxidative-stress-induced SOD-1 GCCCGGCGGATGAAGA CGTCCTTTCAGCAGTCACA
Ischaemia-induced HO-1 CAGGTGTCCAGAGAAGGCTTT TCTTCCAGGGCCGTGTAGAT
eNOS GCAGTGAAGATCTCTGCCTCA AGAATGGTTGCCTTCACACG
Angiogenesis-related VEGF CACGACAGAAGGAGAGCAGAA CGCTGGTAGACGTCCATGA
Apoptosis-related Bax CTG AGCTGA CCTTGG AGC GACTCC AGC CAC AAA GAT G
Bcl-2 CCT GTG GAT GACTGA GTA CCT GAG CAG GGT CTT CAG AGA CA
Bcl-xL GCATCGTGG CCTTTTTCTC C CGA CTG AAG AGT GAG CCC AG
Casp-3 ATG GGA GCA AGT CAGTGG AC CGT ACC AGA GCG AGATGA CA
RGC loss Thy-1 AACTCTTGGCACCATGAACC GGGACACCTGCAAGACTGA
Reference gene ACTB TAGGCACCAGGGTGTGATGGT CATGTCGTCCCAGTTGGTAACA
SOD-1, superoxide dismutase-1; HO-1, heme-oxygenase-1; eNOS, endothelial nitric oxide synthase; VEGF, vascular endothelial growth factor; Bax, Bcl-2-associated
X protein; Bcl-2, B-cell lymphoma 2; Bcl-xL, Bcl-2-like protein 1; Casp-3, cysteine-aspartic acid protease 3;Thy-1, thymocyte cell surface antigen-1; ACTB, mouse beta
actin; RGC, retinal ganglion cell. Kindly provided by Dr. Joseph A. Garcia, from the Department of Internal Medicine, University of Texas Southern Medical Center,
Dallas, TX, USA.
Germany); results were analyzed with a ﬂuorescence microscope
(Fluoview X; Olympus, Tokyo, Japan) at 580 nm wavelength. The
mean number of TUNEL-positive cells per slide was determined
(three consecutive sections per slide, one slide for every 10 sections
of 6μm, total ﬁve slides per eye), with attention to the inter-
nal retinal layers. Findings were compared over time between the
injured (right) and uninjured (left) eyes of the individual mice
and between the injured eyes of the mice that underwent HBO
treatment or were untreated.
GENE EXPRESSION
Forty-seven mice were used for molecular analysis. Immediately
after euthanization at 1, 3, or 21 days following rAION induc-
tion, the retinas were frozen in liquid nitrogen. Total RNA was
extracted with TRIzol™ reagent (Invitrogen, Life Technologies,
Carlsbad, CA, USA), followed by reverse-transcription into cDNA
using random hexamers, according to the manufacturer’s protocol
(Amersham Biosciences, UK), and MMLV-reverse transcriptase
(Promega,Madison,WI,USA). cDNA was analyzed with real-time
polymerase chain reaction (PCR) using the Sequence Detection
System (ABI Prism 7900; Applied Biosystems, Inc. Foster City, CA,
USA). The expression of the following genes was measured: super-
oxide dismutase-1 (SOD-1), heme-oxygenase-1 (HO-1), endothe-
lial nitric oxide synthase (eNOS), vascular endothelial growth
factor (VEGF), Bcl-2, Bax, Bcl-2-like protein 1 (Bcl-xL), cysteine–
aspartic acid protease-3 (Caspase-3), and thymocyte cell surface
antigen-1 (Thy-1); cDNA input levels were normalized against
mouse beta actin (ACTB). Primer pairs of the oxidative-stress-,
ischaemia-, and angiogenesis-related genes were kindly provided
by Joseph A. Garcia, MD, PhD, Department of Internal Medi-
cine, University of Texas Southern Medical Center, Dallas, TX,
USA (Scortegagna et al., 2003; Ding et al., 2005). Reactions were
performed in a 20-μL volume containing 4μL cDNA, 1μL each
of forward and reverse primers, and buffer included in the Mas-
ter Mix (SYBRR Green I; Applied Biosystems, Inc.). The primers
are listed in Table 1. PCR cycling conditions were as follows: ini-
tial denaturation at 50˚C for 2 min; followed by denaturation at
95˚C for 2 min; followed by 40 cycles of denaturation at 95˚C
for 15 s; and annealing and extension at 60˚C for 30 s. Duplicate
transcriptase-based quantitative PCR (RT-QPCR) reactions were
performed for each gene to minimize individual tube variability,
and an average was taken for each time point. Standard curves
were obtained using untreated mouse cDNA for each gene PCR
assay. The results were quantiﬁed by a comparative Ct method,
also known as the 2−Ct method (Giulietti et al., 2001), where:
Ct = Ct(sample) − Ct(reference).
STATISTICAL ANALYSIS
The results were statistically analyzed with the SPSS (SPSS Inc.,
Chicago, IL,USA) forWindows, version 15.0.1. Mean gene expres-
sion was compared between groups by two-way ANOVA. A
P-value of less than 0.05 was considered statistically signiﬁcant.
RESULTS
HISTOLOGICAL CHANGES IN THE RETINA
In the untreated rAION-injured eyes, light microscopy study
revealed cell loss in the RGC layer already at 3 days following
rAION induction (14% loss). Maximal loss of 27% was noted
at 21 days (Figure 2).
The HBO-treated rAION eyes showed only 8% cell loss at
21 days. The inner retinal layers were slightly edematous after
treatment.
APOPTOSIS ASSAY
On TUNEL assay of the untreated rAION-injured eyes, apopto-
sis was noted in the ganglion cell layer. During the ﬁrst 3 days
after rAION induction, only a limited number of TUNEL-positive
RGCs were found. Maximal apoptosis was detected at 7 days after
rAION induction. When ﬁndings were calculated for the whole
eye,we counted 180 positive RGCs at 3 days after rAION induction
and an additional 600 positive RGCs at 7 days (Figure 3).
In the HBO-treated eyes with rAION, apoptotic RGCs were less
abundant. Maximal apoptosis was detected 3 days after rAION
induction. When ﬁndings were calculated for the whole eye, we
counted 97 TUNEL-positive cells in the RGC layer 3 days after
rAION induction, and an additional 164 cells at 7 days.
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FIGURE 2 | Retinal ganglion cells apoptosis 3days after rAION induction.
(A) Untreated eye after rAION induction. Note theTUNEL-positive cells (red)
mainly in the RGC layer. (B) HBO-treated rAION. Note the minimal apoptosis
compared to [(A) ×40]. (C) Uninjured eye; no apoptosis.
FIGURE 3 | Retinal ganglion cells loss following rAION induction. (A) Untreated eye 21 days after rAION induction. Note the RGC loss (arrows). (B)
HBO-treated eye. Note the absence of RGC loss (×40). (C) Uninjured eye (H&E).
Table 2 | Expression of oxidative-stress-induced, ischaemia-induced, and angiogenesis-related genes following rAION induction at various time
points, with and without HBO treatment.
Gene Day 1 Day 3 Day 21
HBO-treated Untreated HBO-treated Untreated HBO-treated Untreated
Oxidative-stress-induced SOD-1 1.16 (±0.3)* 0.82 (±0.2)* 1.00 (±0.3) 0.94 (±0.2) 0.73 (±0.2) 0.97 (±0.5)
Ischemia-induced HO-1 0.74 (±0.4) 1.11 (±0.4) 1.20 (±0.5) 0.73 (±0.4) 1.43 (±1.2) 2.22 (±2)
eNOS 0.99 (±0.3) 1.00 (±0.2) 1.10 (±0.4) 0.75 (±0.3) 1.23 (±0.7)* 0.48 (±0.2)*
Angiogenesis-related VEGF 1.00 (±0.1) 0.88 (±0.1) 0.88 (±0) 0.95 (±0.1) 0.90 (±0) 0.63 (±0.3)
RGC loss Thy-1 1.08 (±0.2) 0.81 (±0.1) 0.90 (±0.2) 1.12 (±0.2) 1.00 (±0.3) 0.73 (±0.4)
Data are expressed in percent (±SD) of levels in uninjured fellow eye.
*Statistically signiﬁcant differences between HBO-treated and untreated mice with AION.
SOD-1, superoxide dismutase-1; HO-1, heme-oxygenase-1; eNOS, endothelial nitric oxide synthase;Thy-1, thymocyte cell surface antigen-1; ACTB, mouse beta actin;
RGC, retinal ganglion cell.
GENE EXPRESSION
Thy-1
Untreated rAION-injured eyes. Thy-1-gene expression gradually
decreased, and by 21 days after rAION induction, levels measured
73% of levels in the non-injured (left) eyes.
HBO-treated rAION-injured eyes. Thy-1 gene expression
remained unchanged relative to levels in the uninjured eyes (NS)
(Tables 2 and 3).
SOD-1
Untreated rAION-injured eyes. Expression of the oxidative-
stress-induced gene, SOD-1, decreased to 82% of the level in the
uninjured (left) eye on day 1 after injury (P < 0.05) and returned
to the uninjured level by day 3.
HBO-treated rAION-injured eyes. SOD-1 gene expression
increased to 116% of levels in the uninjured eyes on day 1
(P < 0.05), returned to the level in the uninjured eyes on day 3 (like
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Table 3 | Expression of apoptosis-related genes following rAION induction at various time points, with and without HBO treatment.
Gene Day 1 Day 3
HBO-treated Untreated HBO-treated Untreated
Proapoptotic Caspase-3 0.97 (±0.29) 0.89 (±0.15) 1.33 (±0.44) 1.20 (±0.28)
Bax 1.13 (±0.46) 1.1 (±0.5) 1.93 (±0.9) 1.71 (±1.28)
Bcl-2 1.12 (±0.49) 1.04 (±0.19) 1.40 (±0.55) 1.11 (±0.3)
Anti-apoptotic Bcl-X 1.26 (±0.41) 1.17 (±0.39) – –
Bax/Bcl-2 1 1.05 1.38 1.54
Bax/Bcl-X 0.90 0.94 – –
There were no statistically signiﬁcant differences (P≥ 0.05) for any of the variables between HBO-treated and untreated mice with AION.
Bax, Bcl-2 associated X protein; Bcl-2, B-cell lymphoma 2; Caspase-3, cysteine-aspartic acid protease 3.
in the untreated rAION eyes), and decreased to 73% of uninjured
eye levels on day 21 (NS).
HO-1 and eNOS
Untreated rAION-injured eyes. Expression of the ischemia-
related genes, HO-1 and eNOS, showed no change on day 1 and
decreased to 73 and 75% of levels in the uninjured (left) eyes,
respectively on day 3. On 21 days, HO-1 expression increased to
222% of levels in the uninjured eyes and eNOS levels decreased to
48% of uninjured eye levels (P = 0.01).
HBO-treated rAION-injured eyes. On day 1, HO-1 decreased
to 74% of levels in the uninjured eye, whereas eNOS expres-
sion showed no change. On day 3, the expression of both genes
increased, to 120 and 110% of levels in the uninjured eye, respec-
tively (NS). On day 21, levels of HO-1 and eNOS increased to 143
and 123% (P = 0.04), respectively.
VEGF
Untreated rAION-injured eyes. VEGF decreased to 88% of levels
in the uninjured eyes on day 1. On day 3, there was no change from
the levels in the uninjured eyes. On day 21, levels dropped to 63%
of uninjured eye levels (NS).
HBO-treated rAION-injured eyes. There was no signiﬁcant
change in VEGF levels at 1, 3, and 21 days after injury induction
(100, 88, and 90%, respectively).
Caspase-3
Untreated rAION-injured eyes. Expression of the proapoptotic
gene,Caspase-3,decreased on day 1–89%of levels in the uninjured
eyes and increased on day 3–120%.
HBO-treated rAION-injured eyes. Caspase-3 levels remained at
the level of the uninjured eyes on day 1 (97%) and increased to
133% of uninjured eye levels on day 3.
Bax
Untreated rAION-injured eyes. Expression of the proapoptotic
Bax gene showed only a mild change (110%) on day 1 and a more
signiﬁcant change, to 171% of uninjured eye levels, on day 3.
HBO-treated rAION-injured eyes. Bax expression increased
from 113% of uninjured eye levels on day 1 to 193% on day 3
(NS).
Bcl-2 and Bcl-X
Untreated rAION-injured eyes. Expression of the anti-apoptotic
Bcl-2 and Bcl-X genes did not change on day 1. On day 3, Bcl-2
mildly increased, to 111% of uninjured eye levels (NS). The
Bax/Bcl-2 ratio showed no change on day 1 and increased to 1.54
on day 3. The Bax/Bcl-x ratio showed no change on day 1 only.
HBO-treated rAION-injured eyes. Bcl-2 increased to 140% of
levels in the uninjured eyes on day 3. The Bax/Bcl-2 ratio was 1.38.
DISCUSSION
The present study shows that HBO treatment is effective in
preserving the RGCs after the induction of rAION. We found
that injured mice treated with HBO had less cell apoptosis than
untreated mice, with non-signiﬁcant differences in the expres-
sion of apoptosis-related genes. We characterized the changes in
genes related to oxidative-stress, ischemia, and angiogenesis in the
injured retinas of the untreated and HBO-treated mice.
The rAION is a rodent model of white matter stroke, resem-
bling central nervous system stroke, with similar characteristics
to AION in humans (Bernstein et al., 2003; Goldenberg-Cohen
et al., 2005; Chen et al., 2008). Studies in rats have shown that
oxygen, when applied early and in high doses, serves as a highly
neuroprotective molecule in transient focal cerebral ischemia
(Hou et al., 2007; Eschenfelder et al., 2008). These ﬁndings suggest
that hyperoxia, acting via multiple direct and indirect mecha-
nisms, could serve as a therapeutic strategy to salvage acutely
ischemic central nervous system tissue. Of the available oxygen
delivery methods, HBO appears to be the most potent (Singhal,
2007). Three previous clinical failures of HBO in patients with
stroke (Singhal, 2007) were apparently attributable to method-
ologic technicalities, such as delayed time to therapy, inadequate
sample size, and use of excessive chamber pressures (Singhal,
2007). Therefore, in the present study, using a model of rAION
induction, we treated the mice three times within the ﬁrst 24 h
after AION induction and once per day thereafter for another
14 days. The chamber pressure was 2 atm, as used in the clinic.
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Each group consisted of at least seven mice. Furthermore, the
previous clinical trials did not assess the long-term beneﬁt of
HBO in patients with tissue reperfusion. The development of
the mouse model of rAION (Bernstein et al., 2003; Goldenberg-
Cohen et al., 2005, 2009), and a more recent primate model (Chen
et al., 2008), has made it possible to compare the histological
effect of HBO and the accompanying changes in expression of
the relevant genes over time. This has important clinical implica-
tions for the combinationof hyperoxygenationwithneuroimaging
and thrombolysis in the treatment of victims of ischemic stroke
(Singhal, 2007).
The neuroprotective effect of HBO in the brain has been
explained molecularly by the prevention of cell apoptosis, which
in turn preserves brain tissue and promotes neurologic functional
recovery (Yin et al., 2003). Our TUNEL ﬁndings of a rescue effect
of HBO on the RGC in a model of optic nerve stroke are sup-
ported by an earlier study of a rodent model of focal cerebral
ischaemia wherein HBO treatment abolished DNA fragmenta-
tion and reduced the number of TUNEL-positive cells in the
brain (Yin et al., 2003). This diminished the infarct area and
led to an improvement in neurologic scores 7 days after reper-
fusion. Others noted that the neuroprotective effect of HBO was
dose-dependent and that HBO yielded better results than nor-
mobaric oxygen in terms of both clinical outcome and infarct
volume reduction (Eschenfelder et al., 2008). Similar neuroprotec-
tive effects of HBO in ischemia-reperfusion injury were reported
in skeletal muscle (Vidigal et al., 2007) and intestine (Bertoletto
et al., 2007). In the ischemic reperfusion model of skeletal mus-
cle, HBO treatment, applied during different periods, prevented
interstitial hemorrhage, development of a neutrophil inﬁltrate,
and cellular necrosis (Vidigal et al., 2007). However, unlike our
study and studies in the brain (Yin et al., 2003), there was no
reduction in the apoptosis index in the muscle. In the study
of rat intestinal mucosa, apoptosis was reduced when HBO was
administered early, during intestinal ischemia, but not when it
was administered later, during ischaemia-reperfusion (Bertoletto
et al., 2007). In our study, mice underwent HBO treatment imme-
diately after rAION induction, and then again daily for up to
14 days.
We examined several upstream apoptosis factors, Bcl-2, Bcl-x,
and Bax, in the mitochondrial pathways, but none of the changes
following HBO treatment were statistically signiﬁcant. Following
the induction of retinal ischemia, as measured by an increase in
IOP, some earlier studies found no change in Bcl-2 expression and
protein levels (Kaneda et al., 1999), whereas others reported an
increase in Bcl-2 protein levels which was maintained for at least
24 h (Produit-Zengafﬁnen et al., 2009). In the present study, fol-
lowing rAION induction, Bcl-2, and Bcl-x levels increased mildly
in the untreated mice and more in the HBO-treated mice, and
further increased on day 3. Bax increased on day 3 as well, more in
the HBO-treated mice. This ﬁnding for the proapoptotic Bax gene
is in line with previous studies in a rat model of ischemic brain
(Isenmann et al., 1997). However, histologically (TUNEL assay),
apoptosis decreased on days 3 and 7 in the HBO-treated eyes
(P < 0.05), with preservation of the RGC on day 21 (P < 0.05).
By contrast, a study of a rat model of middle cerebral artery occlu-
sion reported no change in Bax expression and an increase in Bcl-2
(Li et al., 2009). We did not expect changes in expression of
Caspase-3 gene levels, as it is activated in the protein form,
although it mildly increased in both groups on day 3 (NS).
The mechanism underlying HBO-induced reduction of
ischemia/reperfusion injury may involve the suppression of neu-
trophil adhesion to the endothelial cell surface (Buras and
Reenstra, 2007). Accordingly, prolonged inhibition of nitric oxide
synthesis was found to lead to an oxidant-associated rise in
neutrophic-endothelial adhesion (Niu et al., 1994). In the present
study, HBO treatment reversed the decrease in eNOS expression
seen after rAION induction in the untreated mice (Table 2). Sim-
ilarly, in a previous study, nitrite and nitrate content increased
by 2.2-fold in rats with cardiac infarct treated with normoxia
plus hyperbaria or hyperoxia plus hyperbaria, and the NOS-3
protein level increased by 1.2-fold (Cabigas et al., 2006). The
authors speculated that cardioprotection was directly dependent
on NOS-mediated oxygen availability.
It is not clear how HBO affects the ischemia-induced patho-
physiological responses, such as angiogenesis or skeletal muscle
regeneration (Asano et al., 2007). In our study, the untreated
rAION mice showed an immediate decrease inVEGF levels, which
resolved by day 3 but reappeared on day 21, whereas the HBO-
treated mice showed only a short, non-signiﬁcant reduction in
VEGF levels at all time points (Table 2). These data suggest that
HBO exerts a neuroprotective effect by increasing VEGF levels.
Early studies of optic nerve head damage in rodents reported
transient leakage in the small vessels on ﬂuorescein angiography
(Goldenberg-Cohen et al., 2005). Following severe focal cerebral
ischemia, HBO reduced blood–brain barrier (BBB) damage, and
edema (Veltkamp et al., 2005). However, as there is no clear vaso-
genic edema in the optic nerve ischemic model, the HBO-treated
mice did not show increased vascular permeability, and therefore,
no signiﬁcant change inVEGF levels. Other ischemicmodels of the
hind limbs, but not the central nervous system, reported a slight
increase in levels of VEGF mRNA (Asano et al., 2007), which was
reversed with HBO treatment (Asano et al., 2007).
Heme-oxygenase-1 is known to exert a neuroprotective effect
in ischemic conditions by regulating blood perfusion (Arai-Gaun
et al., 2004). In our study, HO-1 expression increased already
on day 3 after treatment. In the acute phase (day 1), HBO also
prevented a decrease in SOD-1 (P < 0.05), which protects cells
against oxidative-stress (Chan et al., 1994;Nishi et al., 2005).HBO-
enhanced SOD-1 activity during particular periods of reperfusion
has been reported in models of severe brain ischemia, indicating
a potential beneﬁt of treatment (Mrsic-Pelcic et al., 2004b). In a
similar ﬁnding to ours, rats exposed to global cerebral ischemia for
20 min and treated with HBO within 6 h of reperfusion showed no
change in SOD-1 expression (Mrsic-Pelcic et al., 2004a). However,
unlike the present model, no treatment or delayed treatment was
associated with the initial increase in SOD-1.
There are a few limitations to this study. HBO treatment was
induced immediately after rAION induction, whereas in a clini-
cal setting, treatment would likely be delayed at least by several
hours if not a few days. Pilot clinical trials of neuroprotective
agents have failed in part because of an inability to acquire sub-
jects within 48 h of AION onset. Furthermore, even when given
immediately after the acute event, we were not able to prove the
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relevance of HBO treatment in terms of molecular changes in
AION. As opposed to the histological ﬁndings, most of the mol-
ecular differences in this study were not statistically signiﬁcant.
We have therefore described only trends, representing a possi-
ble effect of HBO treatment. However, it should be emphasized
that only SOD-1 and eNOS levels were found to be signiﬁ-
cantly affected, at the early phase and the late phase, respectively,
whereas none of the apoptosis-related genes showed a signiﬁcant
change.
CONCLUSION
Oxygenation has been widely applied in numerous experimental
and clinical conditions (Barach, 2000). The main ﬁnding of this
study is that in a rodent model of AION, RGC loss is reduced
at 21 days after HBO treatment, suggesting that HBO may have
a neuroprotective effect. Although our signiﬁcant ﬁndings were
limited to the histological but not the molecular effect, they
may nevertheless have an important implications for the future
development of treatments for acute ischemia-related visual loss
in humans.
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